Daily Digest

The Valve Wire

Tuesday, May 5, 2026

Executive Summary

As the AATS Annual Meeting opens in full swing, today's digest centers on a critical question for the expanding field of transcatheter tricuspid therapy: does procedural success actually matter for survival? New registry data from the TriSelect study shows that transcatheter tricuspid repair only improves 1-year survival when TR is reduced to moderate or less — patients with residual severe TR fared no better than those who screened out of the procedure entirely. Meanwhile, a propensity-matched study of TAVR vs. SAVR in patients under 70 finds equivalent long-term composite outcomes at 10 years but a threefold higher reintervention rate with TAVR — a finding that directly supports current ACC/AHA and ESC guideline caution about transcatheter-first strategies in younger patients. On the corporate side, Edwards Lifesciences announced a CFO transition and shared 10-year Resilia tissue durability data, while Anteris Technologies reported its first patient treated in its DurAVR pivotal trial.

For the clinical audience: today's literature is dominated by tricuspid and aortic valve studies that sharpen the debate around patient selection, procedural benchmarks, and the durability gap that haunts transcatheter therapies in younger populations. The TriSelect screen-failure analysis (Circulation: Cardiovascular Interventions) is a must-read for anyone building a tricuspid program — it draws a clear line between successful and unsuccessful TTVr in terms of mortality benefit. The under-70 SAVR vs. TAVR comparison in JTCVS Open adds to a growing body of evidence that reintervention risk should weigh heavily in shared decision-making for patients with long life expectancy. And a multicenter NYHA-stratified TAVR outcomes study underscores that functional class IV patients carry dramatically higher 30-day and 1-year mortality — reinforcing the case for earlier intervention rather than waiting until patients are profoundly symptomatic. We also cover new data on TEER across FMR subtypes, global BAV morphology heterogeneity relevant to TAVI planning, and a provocative bioRxiv preprint on how even modest noncoaxial TAVR deployment creates localized thrombogenic microenvironments.

Today's Key Findings

[NOTABLE] TriSelect Registry: Transcatheter tricuspid valve repair improves 1-year survival vs. screen failures — but only when residual TR is reduced to ≤ moderate. Patients with residual TR > moderate had survival equivalent to untreated screen failures. (Circ Cardiovasc Interv)
[NOTABLE] TAVR vs. SAVR in patients <70: At 10-year follow-up, composite outcomes (death, stroke, rehospitalization) were equivalent, but TAVR had a 3.6× higher reintervention hazard. (JTCVS Open)
TRILUMINATE subanalysis: T-TEER with TriClip in patients with prior valve surgery showed 2-year safety and efficacy equivalent to those without prior surgery, with 79% reduction in heart failure hospitalizations. (JTCVS Open)
NYHA class and TAVR outcomes: Pre-procedural NYHA IV independently predicted 8.3% 30-day mortality (vs. 1.4% for NYHA I/II) across 2,256 patients at two German centers. (Front Cardiovasc Med)
FMR subtypes and TEER: Atrial, ventricular, and combined FMR all showed high TEER procedural success (94%) with comparable LA pressure reductions — supporting TEER across the functional MR spectrum. (Am J Cardiol)
Edwards Lifesciences: New CFO appointed (Theodora Mistras); 10-year Resilia tissue durability data presented at AATS; insider stock sales noted.
Anteris Technologies: First patient treated in DurAVR pivotal trial.

Tricuspid Valve (TriClip, TTVR)

Procedural Success Is the Gatekeeper: TriSelect Registry Screen-Failure Analysis

[NOTABLE] A retrospective analysis from the TriSelect registry published in Circulation: Cardiovascular Interventions examined 547 patients evaluated for transcatheter tricuspid valve repair (TTVr) at three US/German centers (2016–2021). Of these, 318 underwent TTVr (61.6% TEER, 38.4% annuloplasty) and 219 (41.9%) were screen failures. Unadjusted 1-year survival was significantly higher in treated patients (82.5% vs. 68.4%, P<0.001), and TTVr was independently associated with lower mortality (HR 0.40, 95% CI 0.18–0.86). However, the survival benefit was entirely driven by procedural success: patients achieving residual TR ≤ moderate had 88.0% survival at 1 year, while those with residual TR > moderate had 69.2% survival — statistically indistinguishable from untreated screen failures (P=0.74).

Editorial perspective: This study crystallizes the "treat well or don't treat" imperative in transcatheter tricuspid intervention. The finding that unsuccessful TTVr confers zero survival advantage over no treatment is a powerful argument for rigorous patient and device selection — and against expanding TTVr indications to anatomies where procedural success is uncertain. That said, important caveats apply: this is non-randomized, retrospective, from experienced centers, and screen failures likely had different risk profiles despite adjustment. The 41.9% screen-failure rate itself raises questions about the maturity of current screening algorithms. These data align with the ESC 2025 Class IIa recommendation for transcatheter TV treatment, which appropriately requires patients to be symptomatic with severe TR and excludes those with severe RV dysfunction. The message for interventionalists: if you can't get the TR to moderate or less, you may not be helping.

TRILUMINATE Subanalysis: T-TEER After Prior Valve Surgery

A subanalysis of the TRILUMINATE Pivotal trial published in JTCVS Open examined 2-year outcomes of TriClip T-TEER in 113 patients with prior valve surgery compared to 356 without. This is a clinically important population — isolated tricuspid surgery after prior left-sided valve operations carries high mortality (historically 8–20%), and many of these patients accumulate progressive TR that goes untreated due to reoperative risk. The results were reassuring: procedural success was 99% in both groups, 30-day adverse events were low and comparable, and at 2 years, TR reduction to ≤ moderate was achieved in 81% vs. 80% (P=0.93). Both groups experienced significant reductions in heart failure hospitalizations (79% reduction in prior surgery group). KCCQ improvements were clinically meaningful (+15 and +16 points).

Editorial perspective: This is exactly the niche where transcatheter tricuspid therapy makes intuitive sense — patients too high-risk for reoperation who would otherwise receive only medical therapy. The 99% procedural success rate in prior surgery patients is notable, though this is a trial population with careful anatomy screening. Real-world applicability will depend on whether these success rates hold outside expert centers. The comparison to the ESC 2025 framework is apt: these patients fit squarely into the Class IIa recommendation for transcatheter TV treatment in high-risk symptomatic patients. The absence of a randomized medical therapy comparator in this subgroup limits causal inference.

Navigating Isolated TR: A Practical Guide

A practical review in JTCVS Open provides a guide to perioperative and periprocedural management of isolated tricuspid regurgitation. While no abstract was available, this type of operational guidance is increasingly needed as both surgical and transcatheter tricuspid programs expand — particularly given the ESC 2025 emphasis on earlier referral and the well-documented "too-late" referral problem that has plagued TR management for decades.

TR Evolution After Transcatheter Mitral Valve-in-Valve Replacement

A retrospective analysis from Guangdong Provincial People's Hospital in JTCVS Open examined TR changes after transcatheter mitral valve-in-valve replacement (TM-ViV) in 96 patients. Among 70 patients with preoperative moderate/severe TR, the proportion with ≥ moderate TR decreased significantly at 1 month (47.3% vs. 72.9%, P<0.001) and 1 year (50.0% vs. 72.9%, P=0.001). No mortality difference was detected between baseline TR groups, though the study was underpowered for this endpoint. The finding that TR improves in many patients after successful mitral ViV is consistent with the concept that left-sided valve disease drives secondary TR — and suggests that concomitant tricuspid intervention may not always be necessary when the mitral problem is addressed.

Aortic Valve (TAVR/TAVI)

TAVR vs. SAVR Under 70: Equivalent Outcomes but Higher Reintervention with TAVR at 10 Years

[NOTABLE] A propensity-matched study in JTCVS Open compared 132 TAVR and 132 SAVR patients under age 70 (mean age 64.9 years, STS-PROM 2.9%) with follow-up extending to 10 years. The primary composite of all-cause death, stroke, and procedure/valve-related hospitalization was similar at 10 years (SAVR 50.8% vs. TAVR 42.9%; HR 1.01, 95% CI 0.66–1.53). However, TAVR patients had significantly higher reintervention rates (10.6% vs. 3.7%, P=0.03) with a flexible parametric model showing a 3.6-fold higher reintervention hazard (HR 3.63, P=0.01). SAVR had more acute kidney injury, bleeding, and new-onset atrial fibrillation perioperatively, while pacemaker rates were similar.

Editorial perspective: This study is directly relevant to the ACC/AHA vs. ESC guideline divide on the age threshold for TAVI. Both guidelines currently recommend SAVR for patients under 65 (ACC/AHA) or 70 (ESC), and this data supports that caution. A 3.6× reintervention hazard is clinically meaningful in patients with potentially 20+ years of life expectancy. While the reintervention difference did not translate into a mortality signal during the study period, lifetime management concerns — coronary access obstruction with TAV-in-TAV, the 12–17% mortality of THV explantation, and progressive patient-prosthesis mismatch — loom large in this age group. The observational, single-center design and potential for residual confounding limit definitive conclusions, but the trajectory is consistent with the randomized trial long-term follow-up data that has made the ESC raise the SAVR-preferred threshold to 70 rather than lower it.

Pre-Procedural NYHA Class as a Mortality Predictor After TAVR

A multicenter study of 2,256 TAVR patients from two German heart centers (2017–2022) published in Frontiers in Cardiovascular Medicine demonstrates that pre-procedural NYHA class IV is independently associated with dramatically worse outcomes: 30-day mortality of 8.3% (vs. 1.4% for NYHA I/II) and 1-year mortality of 19.2% (vs. 5.2%). NYHA IV patients also had significantly higher rates of CPR, vasopressor use, renal replacement therapy, and longer hospital stays. After multivariable adjustment, NYHA IV remained an independent predictor of both 30-day and 1-year mortality.

Editorial perspective: This study underscores a critical tension in the aortic stenosis management paradigm: patients who are sickest at presentation have the worst outcomes, yet current practice often waits for symptoms to become severe before intervening. These findings provide real-world support for the push toward earlier intervention in aortic stenosis — the direction advocated by the EARLY TAVR trial and now reflected in the ESC 2025 IIa recommendation for early intervention in asymptomatic severe AS. If NYHA IV patients face an 8.3% 30-day mortality even with contemporary TAVR, the argument for intervening before they reach that point becomes harder to dismiss.

Global BAV Morphology Heterogeneity: Implications for TAVI Planning

A large CT core-lab analysis of 12,712 patients referred for TAVI across eight global regions, published in Heart, reveals significant geographic variation in bicuspid aortic valve (BAV) prevalence and morphology. BAV prevalence was highest in India (43%) and lowest in Africa (7%). BAV patients were younger, more often male, and had larger annular areas, more horizontal aortas, and more severe calcification. Notably, patients from India and Asia-Pacific had smaller aortic valve complex dimensions and lower coronary ostia height — features that increase procedural complexity.

Editorial perspective: Both ACC/AHA and ESC guidelines rate TAVI for BAV as Class IIb, and BAV patients were excluded from virtually all major TAVI RCTs. This study highlights an underappreciated dimension: BAV is not a homogeneous entity worldwide. The high BAV prevalence in India (43% of TAVI referrals!) combined with smaller anatomy and lower coronary heights creates a particularly challenging procedural landscape. As TAVI expands globally, one-size-fits-all device selection and implantation strategies will not suffice. The data also raise a fundamental question: if nearly half of TAVI referrals in some regions have BAV, we urgently need randomized data in this population rather than continuing to extrapolate from tricuspid aortic valve trials.

TAVR vs. SAVR in Reduced LVEF: Meta-Analysis Finds No Clear Winner

A systematic review and meta-analysis in Cureus compared TAVR and SAVR in patients with severe AS and LVEF ≤50% across seven comparative studies (n=1,651). Thirty-day mortality was not significantly different (RR 0.85, 95% CI 0.46–1.57). TAVR showed a lower early stroke risk (RR 0.48, 95% CI 0.25–0.91), but pacemaker implantation (RR 2.66), 1-year gradients, and LVEF recovery estimates were imprecise. The GRADE certainty was low to very low for most outcomes.

Editorial perspective: Patients with reduced LVEF and severe AS represent a vulnerable subgroup where procedure choice matters enormously, yet this meta-analysis demonstrates how thin the evidence base actually is. The stroke signal favoring TAVR is hypothesis-generating but should be interpreted cautiously given the mix of randomized subgroups and observational data. The imprecision around pacemaker rates and LVEF recovery — arguably the outcomes that matter most in this population — means clinicians are still largely flying blind. Heart Team decision-making, as both guidelines recommend, remains the only defensible approach here.

Valve-in-Valve TAVR: Under-Expansion Matters

A retrospective single-center study of 152 valve-in-valve TAVR patients from Freiburg, published in Clinical Research in Cardiology, demonstrates that under-expansion of self-expanding valves in the waist area correlates with higher postprocedural mean gradients. Post-dilation significantly improved waist expansion (median increase 7.8%, P<0.0001). Deeper implantation depth was associated with worse expansion in self-expanding valves. This is a practical finding for operators performing ViV procedures — periinterventional angiographic assessment of expansion may guide the decision to post-dilate.

Noncoaxial TAVR Deployment and Thrombosis Risk (Preprint)

A bioRxiv preprint using particle image velocimetry and a physiologic blood loop demonstrates that even modest (±10°) transcatheter heart valve canting creates cusp-specific thrombogenic microenvironments not captured by global hemodynamic measures. Anti-curvature canting increased the stasis area in the right coronary cusp sinus to 92% and prolonged neo-sinus washout to 4.7 cycles (vs. 1.8 for along-curvature). Histologic analysis confirmed surface-adherent thrombus in poorly washed regions.

Editorial perspective: This bench study provides a mechanistic explanation for why some TAVR patients develop hypoattenuating leaflet thickening (HALT) while others don't — deployment angle may be a modifiable risk factor. If confirmed in clinical studies, this could influence implantation technique and CT planning, and highlights why the Heart Valve Collaboratory's standardized imaging protocols for transcatheter valve failure are so important.

Additional TAVR Studies

Low-flow AS outcomes by sex: A single-center cohort study of 599 LFAS patients found sex- and subtype-specific outcome differences after TAVR — males showed significant variation in mortality across LFAS subtypes, while females did not. (J Invasive Cardiol)
QRS-T angle dynamics after TAVI: A study of 104 patients showed initial QRS-T angle widening post-TAVI with subsequent narrowing below baseline at 30 days — possibly reflecting hemodynamic normalization. (Int J Med Sci)
Osteosarcopenia predicts adverse TAVI outcomes: In 93 consecutive TAVI patients, preoperative osteosarcopenia (15.1% prevalence) independently predicted the composite of death and unplanned rehospitalization at 1 year. (J Phys Ther Sci)
SGLT2 inhibitor trial protocol: A Japanese RCT protocol will evaluate whether empagliflozin improves diastolic function (E/e') after TAVI in patients with preserved LVEF — an interesting study given the growing recognition of post-TAVI HFpEF. (BMJ Open)
RBBB-like rhythm after TAVR: A case presentation in Circulation describes a new right bundle branch block–like rhythm immediately after TAVR. No abstract was available, but conduction disturbances remain among the most common TAVR complications.
ViV TAVR crossing technique: A JACC Case Reports publication describes a combined snare and buddy-balloon strategy for failed retrograde valve crossing during ViV TAVR — a useful addition to the proceduralist's toolkit for complex anatomy.

Mitral Valve (MitraClip, PASCAL, TMVR)

TEER Works Across All FMR Subtypes: Cleveland Clinic Analysis

A retrospective study from the Cleveland Clinic published in The American Journal of Cardiology analyzed 127 patients with functional MR who underwent TEER, categorized into atrial FMR (24%), ventricular FMR (18%), and combined (58%). Despite distinct baseline echocardiographic and hemodynamic profiles — aFMR patients had lower baseline LA pressures and preserved LV function — all subtypes showed significant post-TEER reductions in LA pressures with high procedural success (94%). This is directly relevant to the ESC 2025's formal recognition of atrial SMR as a distinct entity, supporting the concept that TEER may be effective across the FMR spectrum when appropriate patient selection is applied.

Editorial perspective: While the 94% success rate across subtypes is encouraging, this is a retrospective analysis from a single expert center with only 127 patients and no long-term follow-up. The ESC 2025 guidelines rate TEER for ventricular SMR as Class I (based on COAPT/RESHAPE-HF2) but only Class IIb for atrial SMR in inoperable patients. This study doesn't change those recommendations, but it does suggest that the hemodynamic benefits of TEER are not limited to ventricular pathology. Future prospective data will be needed to determine if the favorable hemodynamics translate into clinical outcomes for aFMR.

Iatrogenic ASD Closure After TMVR: Still No Clear Benefit

A National Inpatient Sample analysis in Cureus identified 4,965 TMVR hospitalizations (2020–2022), of which 431 (8.7%) underwent percutaneous iASD closure during the same admission. After multivariate adjustment, there was no difference in in-hospital mortality, cardiogenic shock, acute heart failure, or cardiac tamponade between closure and non-closure cohorts. The closure group had higher baseline prevalence of pulmonary hypertension (56.9% vs. 40.5%) and heart failure (95.4% vs. 87.9%), suggesting selection bias toward sicker patients. These findings are consistent with the earlier MITHRAS trial, which also showed no benefit of routine closure.

SQ-Kyrin-M TEER System: Chinese Multicenter Trial for DMR

A prospective multicenter study in Structural Heart evaluated the SQ-Kyrin-M TEER system — a novel Chinese-developed device — in 120 patients with high-risk degenerative MR (mean age 71.9, mean STS 9.3%) across 25 sites. At 12 months, clinical success was 82.5%, MR ≤2+ in 91.7%, and MR ≤1+ in 70.4%. All-cause mortality was 7.6%, major adverse events 10.8%, and KCCQ scores improved by 18.9 points. These results are broadly consistent with MitraClip outcomes in similar populations, positioning the SQ-Kyrin-M as a competitive entrant in the growing global TEER device market.

Transcatheter AV Valve Interventions in Congenital Heart Disease

A review in Current Opinion in Cardiology surveys the emerging application of adult transcatheter technologies (TEER, valve-in-valve, annuloplasty) to congenital atrioventricular valve disease. The authors note that imaging complexity and a steep learning curve in standalone pediatric centers remain the primary barriers. The key message: collaboration between adult structural interventionalists and congenital programs will be essential as these technologies mature.

Surgical vs. Transcatheter Comparisons

Today's most significant head-to-head comparison is the under-70 TAVR vs. SAVR study discussed above, showing equivalent 10-year composite outcomes but significantly higher reintervention rates with TAVR. This joins a growing body of long-term evidence that supports both the ACC/AHA (SAVR preferred <65) and ESC (SAVR preferred <70) positions on younger patients. The 3.6× reintervention hazard with TAVR is particularly relevant to the lifetime management concept emphasized in the ESC 2025 guidelines — future valve-in-valve feasibility, coronary access, and patient-prosthesis mismatch must be considered at the index procedure.

Separately, the TAVR vs. SAVR meta-analysis for reduced LVEF found no significant mortality difference at 30 days but a possible TAVR advantage for early stroke (RR 0.48) — though the evidence certainty was very low across outcomes.

Preprint Highlights

The only valve-relevant preprint today is the bioRxiv study on noncoaxial TAVR deployment and sinus thrombogenesis, discussed in detail above. Using particle image velocimetry and whole-blood loop experiments, the investigators demonstrate that even 10° of valve canting creates cusp-specific thrombogenic microenvironments with dramatically increased stasis and prolonged washout, corresponding to histologic thrombus formation. If validated clinically, this could make deployment coaxiality a modifiable procedural target for reducing HALT.

Device & Technology

Anteris Reports First Patient in DurAVR Pivotal Trial

Anteris Technologies (AVR.AX) announced that the first patient has been treated in its pivotal DurAVR THV trial. The DurAVR system is based on single-piece bovine pericardial tissue designed to replicate native aortic valve geometry — a fundamentally different design philosophy from current TAVR valves. The EU early feasibility study (NCT06510855) has enrolled 40 patients and is now active but no longer recruiting. This is a milestone for Anteris, though the DurAVR program remains in early-stage clinical evaluation and any competitive threat to Edwards and Medtronic platforms is years away.

TruLeaf Medical Completes Second-Stage Valve Implantation

TruLeaf Medical, a subsidiary of Allmed Solutions, announced completion of second-stage valve implantation in two additional patients. Details on the valve platform and indication were limited in the press release.

Edwards Lifesciences: 10-Year Resilia Tissue Durability Data

Edwards Lifesciences shared 10-year pivotal data supporting long-term durability of its Resilia tissue platform at AATS. Resilia tissue is used in both surgical (INSPIRIS RESILIA) and transcatheter (SAPIEN 3 Ultra RESILIA) valves, and durability data at this time horizon is increasingly important as the TAVI-eligible population skews younger. The specifics of the presented data were not fully detailed in the press release, but 10-year durability benchmarks are a critical competitive differentiator — particularly as the ESC 2025 guidelines note comparable SVD rates between TAVI and SAVR at up to 10 years while acknowledging potential selection/survival bias.

Wearable-Echo-FM: AI Foundation Model for 1-Lead ECG

A study in European Heart Journal – Digital Health presents Wearable-Echo-FM, a foundation model that uses contrastive pre-training with echocardiographic text reports to enable structural heart disease screening from 1-lead ECGs — the type available on consumer wearables. With only ~1,000 labeled ECGs, the model achieved AUROC of 0.855 for LV systolic dysfunction and 0.819 for diastolic dysfunction. While not a valve-specific device, the ability to screen for structural heart disease from wearable ECGs could dramatically change the upstream detection of valve disease — particularly asymptomatic severe aortic stenosis, where the EARLY TAVR paradigm depends on timely diagnosis.

Industry & Market

Edwards Lifesciences Appoints New CFO

In the day's biggest corporate news, Edwards Lifesciences announced that Theodora (Doretta) Mistras will become Chief Financial Officer, succeeding longtime CFO Scott Ullem. Mistras will receive a $925K salary and significant equity compensation. The transition comes at a pivotal moment for Edwards as it defends market share in TAVR against Medtronic's Evolut platform while investing heavily in tricuspid (EVOQUE), mitral (PASCAL, SAPIEN M3), and emerging surgical tissue platforms. Multiple insider stock sales were also filed (VP Donald Bobo, CVP Lippis), which drew attention from financial media.

AATS Meeting Coverage

Cardiovascular Business covered several AATS themes including surgery vs. GLP-1 drugs for weight-related cardiac outcomes and supra-annular vs. intra-annular valve considerations for redo TAVR. The meeting runs through May 7, and we expect late-breaking trial presentations and simultaneous publications throughout the week.

Predicting Individual TAVR Outcomes

Cardiovascular Business reports on emerging tools for predicting individual patient outcomes after TAVR — part of the broader move toward personalized risk stratification that incorporates osteosarcopenia (see above), biomarkers, and AI-driven models beyond traditional STS-PROM scores.

Financial Analysis

The Edwards Lifesciences CFO transition dominated today's financial news cycle. Theodora Mistras, who will succeed Scott Ullem, inherits a company navigating a complex strategic inflection point: TAVR growth is decelerating in mature markets as penetration plateaus in high/intermediate-risk populations, while expansion into lower-risk and younger patients depends on long-term durability data that is only now emerging. The 10-year Resilia durability presentation at AATS is strategically timed — Edwards needs to demonstrate tissue longevity to defend its position as the ESC 2025 guidelines have lowered the TAVI age threshold to 70 and the ACC/AHA update (expected to incorporate DEDICATE and EARLY TAVR data) could follow suit.

Multiple Edwards insider sales were flagged by financial media (VP Bobo, CVP Lippis, Form 144 filings), though these appear to be routine tax-related dispositions and option exercises rather than discretionary selling. Yahoo Finance nonetheless highlighted potential bearish signals. The new CFO's $925K salary and major equity package suggest the board is investing in a seasoned leader for what promises to be a competitive period — Medtronic's Evolut FX+, Boston Scientific's ACURATE neo2, and emerging challengers like Anteris are all vying for TAVR market share.

The broader medtech market showed weakness: Abbott dropped 2.15% to $87.54 (now down 28.9% over 6 months), Medtronic fell 2.12% to $78.30 (hitting a new 52-week low), and Boston Scientific, despite gaining 0.62%, is down 42.5% over 6 months. Only Edwards (-0.77%) and Anteris (-0.24%) showed relative resilience. The sector-wide selloff reflects macroeconomic headwinds (tariff uncertainty, interest rate expectations) rather than structural heart-specific catalysts, but it creates a valuation backdrop where M&A activity could accelerate if major platforms see acquisition opportunities among smaller structural heart companies.

Valve Industry Stocks

6-Month Valve Industry Stock Performance

Edwards Lifesciences (EW)

Close: $83.33 | Daily Change: -$0.65 (-0.77%)
6-Month Performance: +0.59% ($82.84 → $83.33)
Market Cap: $48.0B | P/E (trailing): 45.04 | P/E (forward): 24.78
Beta: 0.87 | 52-Week Range: $72.30 – $87.89
Analyst Consensus: Buy | Target: $97.15 (range: $84 – $110, 27 analysts)
Next Earnings: July 23, 2026 (EPS est: $0.74 | Rev est: $1.70B)
Key Events: New CFO Theodora Mistras appointed, succeeding Scott Ullem. 10-year Resilia tissue durability data presented at AATS. Multiple insider sales filed (routine tax-related). Stock essentially flat over 6 months despite sector-wide weakness, suggesting relative investor confidence in the structural heart franchise.

Medtronic (MDT)

Close: $78.30 | Daily Change: -$1.70 (-2.12%)
6-Month Performance: -12.04% ($89.01 → $78.30)
Market Cap: $100.5B | P/E (trailing): 21.87 | P/E (forward): 12.92
Beta: 0.63 | 52-Week Range: $78.29 – $106.33
Analyst Consensus: Buy | Target: $108.00 (range: $90 – $121, 25 analysts)
Next Earnings: June 3, 2026 (EPS est: $1.55 | Rev est: $9.62B)
Key Events: Stock hit a new 52-week low at $78.29 today. The 12% decline over 6 months reflects broader portfolio concerns beyond structural heart, but upcoming earnings on June 3 will provide the first detailed look at Evolut FX+ adoption and the structural heart segment's growth trajectory. The Intrepid TMVR pivotal trial continues enrolling (1,056 target). The forward P/E of 12.92 suggests the market is pricing in near-term headwinds.

Abbott (ABT)

Close: $87.54 | Daily Change: -$1.92 (-2.15%)
6-Month Performance: -28.91% ($123.14 → $87.54)
Market Cap: $152.5B | P/E (trailing): 24.52 | P/E (forward): 14.44
Beta: 0.65 | 52-Week Range: $87.30 – $139.06
Analyst Consensus: Buy | Target: $118.64 (range: $92 – $143, 25 analysts)
Next Earnings: July 16, 2026 (EPS est: $1.28 | Rev est: $12.53B)
Key Events: Abbott has been the worst performer among major valve companies over 6 months, down nearly 29%. The structural heart division (MitraClip, TriClip, Navitor TAVR) faces questions about competitive positioning as Edwards and Medtronic advance next-generation platforms. TRILUMINATE 2-year subanalysis data (discussed above) reinforces TriClip's clinical positioning, but Abbott needs top-line commercial catalysts. The $87.30 intraday low approached the 52-week trough.

Boston Scientific (BSX)

Close: $56.85 | Daily Change: +$0.35 (+0.62%)
6-Month Performance: -42.52% ($98.90 → $56.85)
Market Cap: $84.5B | P/E (trailing): 23.79 | P/E (forward): 15.10
Beta: 0.62 | 52-Week Range: $56.05 – $109.50
Analyst Consensus: Strong Buy | Target: $85.19 (range: $60 – $110, 32 analysts)
Next Earnings: July 29, 2026 (EPS est: $0.83 | Rev est: $5.40B)
Key Events: The deepest drawdown in the sector (-42.5% over 6 months). Despite the "Strong Buy" analyst consensus and significant upside to target, BSX is trading near its 52-week low. The ACURATE IDE trial (NCT03735667, 1,948 patients) remains active — results will be pivotal for BSX's TAVR competitive positioning. The Millipede transcatheter annuloplasty program (4 patients enrolled) continues in early feasibility.

Anteris Technologies (AVR.AX)

Close: A$8.33 | Daily Change: -A$0.02 (-0.24%)
6-Month Performance: +21.43% (A$6.86 → A$8.33)
Market Cap: A$0.8B | P/E (forward): -3.82 (pre-revenue)
Beta: 0.59 | 52-Week Range: A$4.68 – A$9.79
Analyst Target: A$13.00 (1 analyst)
Key Events: First patient treated in the DurAVR pivotal trial — a significant milestone for this pre-revenue company. Anteris is the sector outlier, up 21% over 6 months while all major competitors declined. This reflects the speculative premium on the DurAVR single-piece tissue valve concept, but the path to commercialization remains long and high-risk. The EU early feasibility study (NCT06510855, n=40) is active but no longer recruiting.

Private Companies of Note: JenaValve Technology, J Valve Technology, and Meril Life Sciences remain private and are not publicly traded. JC Medical's J-Valve Transfemoral Pivotal Study (NCT06455787) continues recruiting, now affiliated with Edwards Lifesciences.

Market Outlook: The valve industry stock landscape shows a striking bifurcation: large-cap medtech names (ABT, BSX, MDT) are in sharp decline (-12% to -43% over 6 months) driven by macroeconomic factors, while Edwards has shown defensive characteristics (essentially flat) and pre-revenue Anteris has rallied on pipeline milestones. With AATS presentations ongoing and multiple earnings reports in the June-July window, catalysts are imminent. The significant gap between current prices and analyst targets across the sector (15-50% upside) suggests either the market is pricing in substantial macro risk or analysts have been slow to revise estimates. Edwards' upcoming earnings on July 23 will be the structural heart bellwether — look for TAVR procedure volume trends, PASCAL/EVOQUE commercial uptake, and guidance on the impact of potential tariff and reimbursement changes.

Clinical Trial Updates

Aortic Valve Trials

[LANDMARK] Evolut Low Risk Long-Term Follow-up (NCT02701283) — Status: Active, not recruiting | Enrollment: 2,223 | Sponsor: Medtronic | The definitive long-term follow-up of the trial that helped establish TAVI noninferiority in low-risk patients. Extended durability data from this trial will directly influence the next ACC/AHA guideline update and the ongoing debate about TAVI vs. SAVR age thresholds. Updated March 2026.
ACURATE IDE (NCT03735667) — Status: Active, not recruiting | Enrollment: 1,948 | Sponsor: Boston Scientific | Comparing ACURATE neo2 against SAPIEN 3 and Evolut. Results will determine BSX's TAVR competitive positioning. Updated May 4, 2026.
DurAVR THV EU-EFS (NCT06510855) — Status: Active, not recruiting | Enrollment: 40 | Sponsor: Anteris Technologies | First patient just treated in the pivotal program; early feasibility study complete. Updated May 4, 2026.
J-Valve Transfemoral Pivotal (NCT06455787) — Status: Recruiting | Enrollment: 194 | Sponsor: JC Medical/Edwards Lifesciences | Transfemoral aortic valve system with unique grasper mechanism. Updated May 4, 2026.
Evolut FX vs. SAPIEN 3 Ultra Resilia (NCT06470022) — Status: Recruiting | Enrollment: 1,346 | Sponsor: Investigator-initiated (C.J. Terkelsen) | Direct head-to-head comparison of the two market-leading TAVR platforms. Updated April 28, 2026.
TAVI and Gut Microbiota (NCT07565077) — Status: Active, not recruiting | Enrollment: 40 | Sponsor: Insel Gruppe AG/University Hospital Bern | Exploratory study of microbiome changes post-TAVI. Updated May 4, 2026.
Dexmedetomidine Sedation for TAVI (NCT07532733) — Status: Recruiting | Phase: N/A | Enrollment: 80 | Sponsor: Erasme University Hospital | Comparing respiratory/hemodynamic effects of dexmedetomidine vs. propofol/remifentanil sedation. Updated April 30, 2026.
TAVR Sedation Regimen QoR (NCT07556523) — Status: Recruiting | Phase: Phase 4 | Enrollment: 126 | Sponsor: Investigator-initiated (D. Lyubashevsky) | Comparing propofol, dexmedetomidine, and midazolam for post-TAVR quality of recovery. Updated April 29, 2026.
NHLBI-Emory Advanced Cardiac CT (NCT05372627) — Status: Not yet recruiting | Enrollment: 1,000 | Sponsor: NHLBI | Advanced CT reconstruction methods relevant to valve planning. Updated May 4, 2026.

Mitral Valve Repair Trials

[LANDMARK] REPAIR-MR (NCT04198870) — Status: Active, not recruiting | Enrollment: 500 | Sponsor: Abbott | The pivotal RCT comparing MitraClip to surgical repair for primary MR — the most anticipated mitral trial in the field. If MitraClip demonstrates noninferiority for PMR, it could reshape the guideline landscape. Results expected in the coming years.
[LANDMARK] PRIMATY (NCT05051033) — Status: Recruiting | Enrollment: 450 | Sponsor: A. Gelijns (NHLBI-supported) | Comparing mitral valve repair vs. TEER for secondary MR — will extend the evidence base beyond COAPT selection criteria. Updated March 2026.
[LANDMARK] COAPT Long-Term Follow-up (NCT03706833) — Status: Active, not recruiting | Enrollment: 1,247 | Sponsor: Edwards Lifesciences | Now incorporating both PASCAL and MitraClip systems for extended follow-up. The trial that made TEER for SMR a guideline-level therapy. Updated April 2026.
MitraClip G5 Registry (NCT07543874) — Status: Not yet recruiting | Enrollment: 1,000 | Sponsor: University Hospital of Cologne | Registry for the next-generation MitraClip system. Updated May 1, 2026.
Millipede Transcatheter Annuloplasty (NCT04147884) — Status: Active, not recruiting | Enrollment: 4 | Sponsor: Boston Scientific | Very early feasibility for transcatheter mitral annuloplasty — enrollment of only 4 patients suggests the program has been slow to progress. Updated April 28, 2026.
WATCH-TMVR (NCT04494347) — Status: Completed | Enrollment: 25 | Sponsor: Mayo Clinic | Combined MitraClip + Watchman LAAO study. Updated May 1, 2026.

Mitral Valve Replacement Trials

[LANDMARK] Intrepid TMVR Pivotal (NCT03242642) — Status: Recruiting | Enrollment: 1,056 | Sponsor: Medtronic | The largest ongoing TMVR pivotal trial. Intrepid is Medtronic's bid to establish transcatheter mitral valve replacement as a viable therapy for patients beyond TEER candidacy. Enrollment continuing. Updated March 2026.

Tricuspid Valve Repair Trials

[LANDMARK] TRILUMINATE Pivotal (NCT03904147) — Status: Active, not recruiting | Enrollment: 572 | Sponsor: Abbott | The trial that established T-TEER as a guideline-level therapy (ESC 2025 Class IIa). Today's prior-surgery subanalysis adds to the accumulating evidence base. Long-term follow-up continues.
[LANDMARK] CLASP II TR (NCT04097145) — Status: Recruiting | Enrollment: 870 | Sponsor: Edwards Lifesciences | PASCAL system for TR — Edwards' answer to TriClip. The largest tricuspid repair trial currently enrolling. Updated April 2026.

Tricuspid Valve Replacement Trials

[LANDMARK] TRISCEND II (NCT04482062) — Status: Active, not recruiting | Enrollment: 864 | Sponsor: Edwards Lifesciences | The pivotal trial for the EVOQUE transcatheter tricuspid replacement system. TRISCEND II demonstrated superiority for symptoms/QoL vs. medical therapy but with higher bleeding and pacemaker rates. Long-term follow-up ongoing. Updated February 2026.

Social & Conference Highlights

The AATS Annual Meeting (May 3–7, 2026) is in full session. Today's key takeaways include Edwards Lifesciences' presentation of 10-year Resilia tissue durability data — a strategically critical dataset as the TAVI durability debate continues to define the SAVR vs. TAVI treatment boundary. Cardiovascular Business coverage highlighted several themes: surgery vs. GLP-1 drugs for cardiac remodeling, supra-annular vs. intra-annular valve considerations in redo TAVR, and the general tension between surgical and transcatheter innovation that characterizes every AATS meeting. Expect late-breaking clinical trial presentations and simultaneous publications for the remainder of the week — we'll cover them as they emerge.

Looking Ahead: The AATS Annual Meeting continues through May 7 — watch for late-breaking presentations on surgical and transcatheter valve outcomes, potential simultaneous publications, and industry press conferences. Medtronic earnings on June 3 will provide the next major financial catalyst for the sector. Tomorrow's digest will cover Day 3 presentations and any new publications timed to the meeting. As always, the evidence evolves — stay critical, stay curious.

— E. Nolan Beckett | The Valve Wire

← May 4, 2026